BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004;11:243-250. [PMID: 15117326 DOI: 10.1111/j.1365-2893.2004.00490.x] [Cited by in Crossref: 115] [Cited by in F6Publishing: 106] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Ishigami M, Hayashi K, Katano Y, Itoh A, Hirooka Y, Goto H. Impact of early elevation of serum bilirubin during treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C: Serum bilirubin during PEG IFN and ribavirin. Hepatology Research 2010;40:963-70. [DOI: 10.1111/j.1872-034x.2010.00711.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
2 Keefe B. Interferon-induced depression in hepatitis C: An update. Curr Psychiatry Rep 2007;9:255-61. [DOI: 10.1007/s11920-007-0028-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
3 Kawaguchi Y, Mizuta T, Takahashi K, Iwane S, Ario K, Kawasoe H, Hamaoka K, Eguchi Y, Yasutake T, Shigematsu H, Kawazoe S, Fukushima N, Ozaki I, Fujimoto K. High-dose vitamins E and C supplementation prevents ribavirin-induced hemolytic anemia in patients with chronic hepatitis C. Hepatology Research 2007;37:317-24. [DOI: 10.1111/j.1872-034x.2007.00039.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Sherman M, Cohen L, Cooper MA, Elkashab M, Feinman V, Fletcher D, Girgrah N, Heathcote J, Levstik M, McNaull WB, Wong D, Wong F, Yim C. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006;20:479-85. [PMID: 16858501 DOI: 10.1155/2006/497059] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
5 Giard JM, Terrault NA. Women with Cirrhosis: Prevalence, Natural History, and Management. Gastroenterol Clin North Am. 2016;45:345-358. [PMID: 27261903 DOI: 10.1016/j.gtc.2016.02.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
6 Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA. Racial differences in hepatitis C treatment eligibility. Hepatology. 2011;54:70-78. [PMID: 21488082 DOI: 10.1002/hep.24358] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
7 Asnis GM, De La Garza R 2nd. Interferon-induced depression: strategies in treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:808-18. [PMID: 15907352 DOI: 10.1016/j.pnpbp.2005.03.006] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
8 Honda T, Katano Y, Urano F, Murayama M, Hayashi K, Ishigami M, Nakano I, Yoshioka K, Toyoda H, Kumada T. Efficacy of ribavirin plus interferon-alpha in patients aged > or=60 years with chronic hepatitis C. J Gastroenterol Hepatol. 2007;22:989-995. [PMID: 17608843 DOI: 10.1111/j.1440-1746.2006.04773.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
9 El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to therapy. World J Gastroenterol 2009; 15(40): 4993-4999 [PMID: 19859990 DOI: 10.3748/wjg.15.4993] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
10 Falasca K, Ucciferri C, Mancino P, Gorgoretti V, Pizzigallo E, Vecchiet J. Use of epoetin beta during combination therapy of infection with hepatitis c virus with ribavirin improves a sustained viral response. J Med Virol 2010;82:49-56. [PMID: 19950239 DOI: 10.1002/jmv.21657] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
11 Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, Sjogren M, Farmer D, Ramsey L, Terra K, Gujral H, Gurung C, Srishord M, Fang Y. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment. J Viral Hepat 2008;15:370-8. [PMID: 18194172 DOI: 10.1111/j.1365-2893.2007.00956.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
12 Bhattacharya D, Umbleja T, Carrat F, Chung RT, Peters MG, Torriani F, Andersen J, Currier JS. Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 2010;55:170-5. [PMID: 20622678 DOI: 10.1097/QAI.0b013e3181e36420] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
13 O'Brien C. Issues in designing and interpreting clinical trials of treatments for chronic hepatitis C. J Viral Hepat 2006;13 Suppl 1:6-14. [PMID: 16630042 DOI: 10.1111/j.1365-2893.2006.00757.x] [Reference Citation Analysis]
14 Balan V, Schwartz D, Wu GY, Muir AJ, Ghalib R, Jackson J, Keeffe EB, Rossaro L, Burnett A, Goon BL, Bowers PJ, Leitz GJ; HCV Natural History Study Group. Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. Am J Gastroenterol 2005;100:299-307. [PMID: 15667486 DOI: 10.1111/j.1572-0241.2005.40757.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
15 Huang CF, Huang CI, Yeh ML, Hou C, Hou NJ, Hsieh MY, Huang JF, Chen SC, Lin ZY, Dai CY, Chuang WL, Yu ML. Disease severity and erythropoiesis in chronic hepatitis C. J Gastroenterol Hepatol 2017;32:864-9. [PMID: 27637864 DOI: 10.1111/jgh.13600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
16 Iacobellis A, Ippolito A, Andriulli A. Antiviral therapy in hepatitis C virus cirrhotic patients in compensated and decompensated condition. World J Gastroenterol 2008; 14(42): 6467-6472 [PMID: 19030197 DOI: 10.3748/wjg.14.6467] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
17 Thevenot T, Di Martino V, Lunel-fabiani F, Vanlemmens C, Becker M, Bronowicki J, Bresson-hadni S, Miguet J. Traitements complémentaires de l’hépatite chronique virale C. Gastroentérologie Clinique et Biologique 2006;30:197-214. [DOI: 10.1016/s0399-8320(06)73154-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
18 Honda T, Katano Y, Shimizu J, Ishizu Y, Doizaki M, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I. Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C. Liver Int. 2010;30:527-537. [PMID: 19523048 DOI: 10.1111/j.1478-3231.2009.02064.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]
19 Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009;7:397-414; quiz 366. [PMID: 19114127 DOI: 10.1016/j.cgh.2008.11.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
20 Asthana S, Shukla S, Vargiu AV, Ceccarelli M, Ruggerone P, Paglietti G, Marongiu ME, Blois S, Giliberti G, La Colla P. Different Molecular Mechanisms of Inhibition of Bovine Viral Diarrhea Virus and Hepatitis C Virus RNA-Dependent RNA Polymerases by a Novel Benzimidazole. Biochemistry 2013;52:3752-64. [DOI: 10.1021/bi400107h] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
21 Farrell CP, Mercogliano G, Navarro VJ, Rossi S. Taribavirin: potential future in the treatment of hepatitis C. Future Virology 2011;6:147-55. [DOI: 10.2217/fvl.10.81] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
22 Choi IS, Kim KM, Shim SG. Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study. Arab J Gastroenterol 2021;22:23-7. [PMID: 33223391 DOI: 10.1016/j.ajg.2020.09.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 . Erythropoietin Does Not Increase the Frequency of Thromboembolic Events or Hepatocellular Carcinoma in Hepatitis C Patients Treated With Combination Antiviral Therapy. The American Journal of Gastroenterology 2008;103:2161-2. [DOI: 10.1111/j.1572-0241.2008.01982_18.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
24 Stickel F, Helbling B, Heim M, Geier A, Hirschi C, Terziroli B, Wehr K, De Gottardi A, Negro F, Gerlach T. Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C: EPO and hepatitis C treatment. Journal of Viral Hepatitis 2012;19:77-87. [DOI: 10.1111/j.1365-2893.2011.01527.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
25 Rivkin AM, Chawla S. Epoetin alfa for the treatment of combination therapy-induced hemolytic anemia in patients infected with hepatitis C virus. Pharmacotherapy 2005;25:862-75. [PMID: 15927905 DOI: 10.1592/phco.2005.25.6.862] [Reference Citation Analysis]
26 Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon. 2011;11:968-974. [PMID: 22368680 DOI: 10.5812/kowsar.1735143x.4223] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Donnerer J, Grahovac M, Stelzl E, Kessler HH, Bankuti C, Stadlbauer V, Stauber RE. Ribavirin Levels and Haemoglobin Decline in Early Virological Responders and Non-Responders to Hepatitis C Virus Combination Therapy. Pharmacology 2006;76:136-40. [DOI: 10.1159/000090942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
28 Cainelli F. Hepatitis C virus infection in the elderly: epidemiology, natural history and management. Drugs Aging 2008;25:9-18. [PMID: 18184025 DOI: 10.2165/00002512-200825010-00002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
29 Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39:1147-1171. [PMID: 15057920 DOI: 10.1002/hep.20119] [Cited by in Crossref: 1226] [Cited by in F6Publishing: 1119] [Article Influence: 68.1] [Reference Citation Analysis]
30 Reddy KR, Nelson DR, Zeuzem S. Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol. 2009;50:402-411. [PMID: 19091439 DOI: 10.1016/j.jhep.2008.11.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
31 Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev. 2014;2:CD005441. [PMID: 24585509 DOI: 10.1002/14651858.cd005441.pub3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
32 Hynicka LM, Heil EL. Anemia management in patients with chronic viral hepatitis C. Ann Pharmacother. 2013;47:228-236. [PMID: 23386076 DOI: 10.1345/aph.1R513] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
33 Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ. Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Hepatology. 2013;57:974-984. [PMID: 23081753 DOI: 10.1002/hep.26096] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 5.8] [Reference Citation Analysis]
34 Simón-Talero M, Buti M, Esteban R. Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? J Viral Hepat 2012;19 Suppl 1:14-7. [PMID: 22233409 DOI: 10.1111/j.1365-2893.2011.01521.x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
35 Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Volti GL, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17(39): 4414-4420 [PMID: 22110268 DOI: 10.3748/wjg.v17.i39.4414] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
36 Gish RG, Arora S, Rajender Reddy K, Nelson DR, O’brien C, Xu Y, Murphy B. Virological response and safety outcomes in therapy–naïve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: A randomized, phase 2 study. Journal of Hepatology 2007;47:51-9. [DOI: 10.1016/j.jhep.2007.02.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
37 McHutchison JG, Manns MP, Longo DL. Definition and management of anemia in patients infected with hepatitis C virus. Liver Int 2006;26:389-98. [PMID: 16629641 DOI: 10.1111/j.1478-3231.2006.01228.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
38 Morello J, Rodriguez-novoa S, Jimenez-nacher I, Soriano V. Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. Journal of Antimicrobial Chemotherapy 2008;62:1174-80. [DOI: 10.1093/jac/dkn421] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 4.5] [Reference Citation Analysis]
39 Clark PJ, Aghemo A, Degasperi E, Galmozzi E, Urban TJ, Vock DM, Patel K, Thompson AJ, Rumi MG, D’Ambrosio R. Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. J Viral Hepat. 2013;20:858-866. [PMID: 24304455 DOI: 10.1111/jvh.12113] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
40 Tsiakalos A, Voumvas T, Psarris A, Oikonomou CK, Ziogas DC, Ketikoglou I, Hatzis G, Sipsas NV. Circulating autoantibodies to endogenous erythropoietin are associated with chronic hepatitis C virus infection-related anemia. Hepatobiliary Pancreat Dis Int 2017;16:289-95. [PMID: 28603097 DOI: 10.1016/s1499-3872(16)60131-5] [Reference Citation Analysis]
41 Pockros PJ, Shiffman ML, Schiff ER, Sulkowski MS, Younossi Z, Dieterich DT, Wright TL, Mody SH, Tang KL, Goon BL, Bowers PJ, Leitz G, Afdhal NH; PROACTIVE Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40:1450-1458. [PMID: 15565613 DOI: 10.1002/hep.20482] [Cited by in Crossref: 110] [Cited by in F6Publishing: 106] [Article Influence: 6.1] [Reference Citation Analysis]
42 Dominguez S, Ghosn J, Cassard B, Melica G, Poizot-Martin I, Solas C, Lascaux AS, Bouvier-Alias M, Katlama C, Lévy Y, Peytavin G. Erythrocyte and plasma ribavirin concentrations in the assessment of early and sustained virological responses to pegylated interferon-alpha 2a and ribavirin in patients coinfected with hepatitis C virus and HIV. J Antimicrob Chemother 2012;67:1449-52. [PMID: 22396433 DOI: 10.1093/jac/dks045] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
43 Lamers MH, Broekman M, Drenth JP, Gluud C. Aminoadamantanes versus other antiviral drugs for chronic hepatitis C. Cochrane Database Syst Rev 2014;:CD011132. [PMID: 24937404 DOI: 10.1002/14651858.CD011132.pub2] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
44 Núñez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S, Asensi V, Barreiro P, Garcia-Samaniego J, Soriano V; PRESCO Team. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat 2008;15:363-9. [PMID: 18179454 DOI: 10.1111/j.1365-2893.2007.00952.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
45 Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat 2007;14:371-86. [PMID: 17501757 DOI: 10.1111/j.1365-2893.2006.00816.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
46 Skabelund AJ, Hauser TR, Goist KJ. Pure red cell aplasia caused by ribavirin and interferon treatment. Clin J Gastroenterol 2011;4:313-7. [PMID: 26189631 DOI: 10.1007/s12328-011-0235-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
47 Griesbeck M, Altfeld M. Sex Differences in the Manifestations of HIV-1 Infection. In: Klein SL, Roberts CW, editors. Sex and Gender Differences in Infection and Treatments for Infectious Diseases. Cham: Springer International Publishing; 2015. pp. 103-81. [DOI: 10.1007/978-3-319-16438-0_5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
48 Farley JE, Dial DJ, Littleton-kearney M. Management of Hematologic and Neuropsychiatric Side Effects in Treatment of Chronic HCV Infection. The Journal for Nurse Practitioners 2006;2:38-45. [DOI: 10.1016/j.nurpra.2005.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
49 Alavian S, Tabatabaei SV, Behnava B. Impact of erythropoietin on sustained virological response to peginterferon and ribavirin therapy for HCV infection: a systematic review and meta-analysis: Impact of erythropoietin on sustained virological response. Journal of Viral Hepatitis 2012;19:88-93. [DOI: 10.1111/j.1365-2893.2011.01532.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
50 Hung C, Lee C, Lu S, Wang J, Chen C, Hu T, Kee K, Chang K, Tseng P, Yen Y, Changchien C. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006;26:1079-86. [DOI: 10.1111/j.1478-3231.2006.01354.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
51 Tseng K, Chen L, Chen C, Chang T, Chou A, Wu I, Cheng P. Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b. Hepatology Research 2009;39:539-45. [DOI: 10.1111/j.1872-034x.2009.00489.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
52 Smit C, Arends J, Peters L, Montforte Ad, Dabis F, Zangerle R, Daikos G, Mussini C, Mallolas J, de Wit S, Zinkernagel A, Cosin J, Chene G, Raben D, Rockstroh J; Hepatitis C- working group for COHERE in Eurocoord. Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord. BMC Infect Dis 2015;15:498. [PMID: 26537918 DOI: 10.1186/s12879-015-1224-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
53 Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, Horne FM, Huebner RE, Janoff EN, Justice AC, Kuritzkes D, Nayfield SG, Plaeger SF, Schmader KE, Ashworth JR, Campanelli C, Clayton CP, Rada B, Woolard NF, High KP. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47:542-53. [PMID: 18627268 DOI: 10.1086/590150] [Cited by in Crossref: 369] [Cited by in F6Publishing: 355] [Article Influence: 26.4] [Reference Citation Analysis]
54 Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45:806-816. [PMID: 17326207 DOI: 10.1002/hep.21565] [Cited by in Crossref: 128] [Cited by in F6Publishing: 130] [Article Influence: 8.5] [Reference Citation Analysis]
55 Chen CC, Tung SY, Wei KL, Shen CH, Chang TS, Chen WM, Xu HW, Yen CW, Chen YH, Lu SN, Hung CH. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc 2020;119:532-7. [PMID: 31445848 DOI: 10.1016/j.jfma.2019.07.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Nguyen DL, Morgan TR. Management of Adverse Events During the Treatment of Chronic Hepatitis C Infection. Clin Liver Dis (Hoboken) 2012;1:54-7. [PMID: 25688295 DOI: 10.1002/cld.33] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
57 Kobayashi T, Hige S, Terashita K, Nakai M, Horimoto H, Sho T, Nakanishi M, Ogawa K, Chuma M, Sakamoto N. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. J Gastroenterol. 2012;47:1228-1237. [PMID: 22460221 DOI: 10.1007/s00535-012-0579-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
58 Van Vlerken LG, Van Soest H, Janssen MP, Boland GJ, Drenth JP, Burger DM, Siersema PD, Van Erpecum KJ. Suboptimal endogenous erythropoietin response in chronic hepatitis C patients during ribavirin and PEG interferon treatment: . European Journal of Gastroenterology & Hepatology 2010;22:1308-15. [DOI: 10.1097/meg.0b013e32833e784d] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
59 Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, Shiffman ML, Yurdaydin C, Dalgard O. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol. 2011;8:212-223. [PMID: 21386812 DOI: 10.1038/nrgastro.2011.21] [Cited by in Crossref: 93] [Cited by in F6Publishing: 89] [Article Influence: 8.5] [Reference Citation Analysis]
60 Quiles-pérez R, Pavón-castillero EJ, Muñoz-de-rueda P, Carmona I, Salmerón J. Valor de la genética en la era de la terapia triple frente al virus de la hepatitis C. Gastroenterología y Hepatología 2014;37:427-37. [DOI: 10.1016/j.gastrohep.2014.04.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Ahn YH, Park H, Lee MJ, Kim DH, Cho SB, Cho E, Jun CH, Choi SK. Comparison of the Clinical Characteristics and Outcomes between Leprosy-Affected Persons in Sorokdo and the General Population Affected by Chronic Hepatitis C in Korea. Gut Liver 2019;13:549-56. [PMID: 30970433 DOI: 10.5009/gnl18432] [Reference Citation Analysis]
62 Henry DH, Slim J, Lamarca A, Bowers P, Leitz G; HIV/HCV Coinfection Natural History Study Group. Natural history of anemia associated with interferon/ribavirin therapy for patients with HIV/HCV coinfection. AIDS Res Hum Retroviruses 2007;23:1-9. [PMID: 17263626 DOI: 10.1089/aid.2006.0082] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
63 Lamers MH, Broekman M, Drenth JP, Gluud C. Aminoadamantanes for chronic hepatitis C. Cochrane Database Syst Rev 2014;:CD010125. [PMID: 24793264 DOI: 10.1002/14651858.CD010125.pub2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Kearney KR, Thornton JJ, Navarro VJ. Taribavirin for the treatment of chronic hepatitis C. Expert Opinion on Pharmacotherapy 2008;9:3243-9. [DOI: 10.1517/14656560802594459] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
65 Benhamou Y, Afdhal NH, Nelson DR, Shiffman ML, Halliman DG, Heise J, Chun E, Pockros PJ. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Hepatology. 2009;50:717-726. [PMID: 19585653 DOI: 10.1002/hep.23073] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
66 Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK. Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1. Hepatology. 2011;53:1109-1117. [PMID: 21480317 DOI: 10.1002/hep.24180] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
67 Suwantarat N, Tice AD, Khawcharoenporn T, Chow DC. Weight loss, leukopenia and thrombocytopenia associated with sustained virologic response to Hepatitis C treatment. Int J Med Sci 2010;7:36-42. [PMID: 20107528 DOI: 10.7150/ijms.7.36] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
68 Krishnan SM, Dixit NM. Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. PLoS Comput Biol 2011;7:e1001072. [PMID: 21304937 DOI: 10.1371/journal.pcbi.1001072] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
69 Eskesen AN, Melum E, Moghaddam A, Bjøro K, Verbaan H, Ring-Larsen H, Dalgard O. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol. 2012;24:890-896. [PMID: 22584257 DOI: 10.1097/meg.0b013e3283546efd] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
70 Martin P, Jensen DM. Ribavirin in the treatment of chronic hepatitis C. J Gastroenterol Hepatol. 2008;23:844-855. [PMID: 18565019 DOI: 10.1111/j.1440-1746.2008.05398.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
71 Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group. Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Aliment Pharmacol Ther 2012;36:370-8. [PMID: 22708649 DOI: 10.1111/j.1365-2036.2012.05188.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
72 Iacobellis A, Andriulli A. Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection. Expert Opinion on Pharmacotherapy 2009;10:1929-38. [DOI: 10.1517/14656560903066811] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
73 Benhamou Y. Anemia and clinical outcomes in hepatitis C. Journal of Hepatology 2007;47:7-9. [DOI: 10.1016/j.jhep.2007.04.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
74 Tsai SM, Kao JT, Tsai YF. How hepatitis C patients manage the treatment process of pegylated interferon and ribavirin therapy: a qualitative study. BMC Health Serv Res 2016;16:247. [PMID: 27402141 DOI: 10.1186/s12913-016-1503-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Solas C, Paré M, Quaranta S, Stanke-Labesque F; pour le groupe Suivi Thérapeutique Pharmacologique de la Société Francaise de Pharmacologie et de Thérapeutique. [Not Available]. Therapie 2011;66:221-30. [PMID: 27393202 DOI: 10.2515/therapie/2011036] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
76 McHutchison JG, Manns MP, Brown RS Jr, Reddy KR, Shiffman ML, Wong JB. Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. Am J Gastroenterol 2007;102:880-9. [PMID: 17397412 DOI: 10.1111/j.1572-0241.2007.01139.x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]
77 Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, Librant-Suska M, Lojewski W, Jurczyk K, Musialik J, Postawa-Klosińska B, Wroblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Pisula A, Lapinski T, Kryczka W, Horban A, Dobracki W. Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study. Medicine (Baltimore) 2015;94:e1411. [PMID: 26402801 DOI: 10.1097/MD.0000000000001411] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
78 Hu C, Weng C, Lin C, Tien H, Kuo Y, Chien C, Yen C, Lin C, Chien R. Predictors of Changes in Hemoglobin Levels in Patients with Chronic Hepatitis C Treated with Ribavirin Plus Pegylated Interferon-α. Renal Failure 2012;34:429-34. [DOI: 10.3109/0886022x.2011.650562] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
79 Marcellin P, Gish RG, Gitlin N, Heise J, Halliman DG, Chun E, Rodriguez-Torres M. Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. J Hepatol 2010;52:32-8. [PMID: 19913323 DOI: 10.1016/j.jhep.2009.10.015] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
80 Poordad F, Lawitz E, Reddy KR, Afdhal NH, Hézode C, Zeuzem S, Lee SS, Calleja JL, Brown RS Jr, Craxi A, Wedemeyer H, Nyberg L, Nelson DR, Rossaro L, Balart L, Morgan TR, Bacon BR, Flamm SL, Kowdley KV, Deng W, Koury KJ, Pedicone LD, Dutko FJ, Burroughs MH, Alves K, Wahl J, Brass CA, Albrecht JK, Sulkowski MS; Protocol 6086 Investigators. Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology 2013;145:1035-1044.e5. [PMID: 23924660 DOI: 10.1053/j.gastro.2013.07.051] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
81 Amanzada A, Goralczyk AD, Reinhardt L, Moriconi F, Cameron S, Mihm S. Erythropoietin rs1617640 G allele associates with an attenuated rise of serum erythropoietin and a marked decline of hemoglobin in hepatitis C patients undergoing antiviral therapy. BMC Infect Dis 2014;14:503. [PMID: 25227310 DOI: 10.1186/1471-2334-14-503] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
82 Nikolova K, Gluud C, Grevstad B, Jakobsen JC. Nitazoxanide for chronic hepatitis C. Cochrane Database Syst Rev. 2014;CD009182. [PMID: 24706397 DOI: 10.1002/14651858.cd009182.pub2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
83 Borroni G, Cazzaniga M, Andreoletti M, Ceriani R, Guerzoni P, Omazzi B, Pich MGL, Prada A, Spinzi G, Terreni N, Salerno F. Low glomerular filtration rate is a risk factor for ribavirin-associated anaemia in old patients with chronic hepatitis C. J Viral Hepat 2013;20:e90-5. [DOI: 10.1111/jvh.12015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
84 Butt AA, McGinnis KA, Skanderson M, Justice AC. Hepatitis C treatment completion rates in routine clinical care. Liver Int 2010;30:240-50. [PMID: 19889081 DOI: 10.1111/j.1478-3231.2009.02156.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 3.7] [Reference Citation Analysis]
85 Deming P, Arora S. Taribavirin in the treatment of hepatitis C. Expert Opinion on Investigational Drugs 2011;20:1435-43. [DOI: 10.1517/13543784.2011.606214] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
86 Bichoupan K, Schwartz JM, Martel-Laferriere V, Giannattasio ER, Marfo K, Odin JA, Liu LU, Schiano TD, Perumalswami P, Bansal M, Gaglio PJ, Kalia H, Dieterich DT, Branch AD, Reinus JF. Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Aliment Pharmacol Ther 2014;39:209-16. [PMID: 24266536 DOI: 10.1111/apt.12560] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
87 Curry MP, Afdhal NH. Use of Growth Factors with Antiviral Therapy for Chronic Hepatitis C. Clinics in Liver Disease 2005;9:439-51. [DOI: 10.1016/j.cld.2005.05.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 1.2] [Reference Citation Analysis]
88 Tseng CW, Hsieh YH, Chang CK, Lai NS, Hung TH, Wu SF, Tseng KC. HLA-B*15:02 is associated with anemia in patients with chronic hepatitis C treated with pegylated interferon-α and ribavirin. Tissue Antigens 2012;80:424-30. [PMID: 22931407 DOI: 10.1111/j.1399-0039.2012.01956.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
89 Bani-Sadr F, Goderel I, Penalba C, Billaud E, Doll J, Welker Y, Cacoub P, Pol S, Perronne C, Carrat F; ANRS HC02 - Ribavic Study team. Risk factors for anaemia in human immunodeficiency virus/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. J Viral Hepat 2007;14:639-44. [PMID: 17697016 DOI: 10.1111/j.1365-2893.2007.00846.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.2] [Reference Citation Analysis]
90 Rendon AL, Nunez M, Romero M, Barreiro P, Martin-Carbonero L, Garcia-Samaniego J, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr. 2005;39:401-405. [PMID: 16010160 DOI: 10.1097/01.qai.0000170034.90438.68] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
91 Demelia L, Civolani A, Murgia D, Murru A, Sorbello O, Rizzetto M. Tolerability of Peg interferon-α2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency. Journal of Hepatology 2007;46:171-3. [DOI: 10.1016/j.jhep.2006.10.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM. Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol. 2008;103:1981-1988. [PMID: 18796095 DOI: 10.1111/j.1572-0241.2008.01957.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
93 Afdhal NH. Role of epoetin alfa in maintaining ribavirin dose. Gastroenterology Clinics of North America 2004;33:25-35. [DOI: 10.1016/j.gtc.2003.12.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
94 Zaily DG, Marlen CF, Santiago DC, Gillian MD, Carmen VS, Zurina CE, Enrique R AS, Liz AL, Lisset GF, Sacha LDV, Elena FB. Clinical Evaluation of Terap C Vaccine in Combined Treatment with Interferon and Ribavirin in Patients with Hepatitis C. Curr Ther Res Clin Exp 2017;85:20-8. [PMID: 29158855 DOI: 10.1016/j.curtheres.2017.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Balestrieri C, Serra G, Cauli C, Chessa L, Balestrieri A, Farci P. Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? Blood 2006;107:3409-10. [DOI: 10.1182/blood-2005-11-4508] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
96 Beisel C, Heuer M, Otto B, Jochum J, Schmiedel S, Hertling S, Degen O, Lüth S, van Lunzen J, Schulze Zur Wiesch J. German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients. AIDS Res Ther 2014;11:16. [PMID: 25006340 DOI: 10.1186/1742-6405-11-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
97 Leung Y, Urbanski SJ, Schindel L, Myers RP. Ischemic colitis during pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Can J Gastroenterol 2006;20:661-3. [PMID: 17066158 DOI: 10.1155/2006/687836] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
98 Saab S, Oh MK, Ibrahim AB, Durazo F, Han S, Yersiz H, Farmer DG, Ghobrial RM, Goldstein LI, Tong MJ, Busuttil RW. Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C. Liver Transpl 2007;13:1032-8. [DOI: 10.1002/lt.21184] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
99 Saito H, Tada S, Ebinuma H, Ishii H, Kashiwazaki K, Takahashi M, Tsukada N, Nishida J, Tanaka S, Shiozaki H, Hibi T. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006;44:3562-8. [PMID: 17021083 DOI: 10.1128/JCM.00079-06] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
100 Bodeau S, Nguyen-Khac E, Solas C, Bennis Y, Capron D, Duverlie G, Brochot E. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations. J Clin Pharmacol 2015;55:517-24. [PMID: 25535910 DOI: 10.1002/jcph.454] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
101 Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5. [PMID: 19152711 DOI: 10.1186/1471-230X-9-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
102 Sulkowski MS. Management of the Hematologic Complications of Hepatitis C Therapy. Clinics in Liver Disease 2005;9:601-16. [DOI: 10.1016/j.cld.2005.07.007] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 1.6] [Reference Citation Analysis]
103 Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM, Herrine SK, Harrison SA, Poordad FF, Koury K. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010;139:1602-1611, 1611.e1. [PMID: 20723545 DOI: 10.1053/j.gastro.2010.07.059] [Cited by in Crossref: 85] [Cited by in F6Publishing: 74] [Article Influence: 7.1] [Reference Citation Analysis]
104 Domingo P, Guardiola JM, Salazar J, Torres F, Mateo MG, Pacho C, Del Mar Gutierrez M, Lamarca K, Fontanet A, Martin J. Association of ITPA gene polymorphisms and the risk of ribavirin-induced anemia in HIV/hepatitis C virus (HCV)-coinfected patients receiving HCV combination therapy. Antimicrob Agents Chemother. 2012;56:2987-2993. [PMID: 22430973 DOI: 10.1128/aac.06473-11] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
105 Bezemer G, Van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, Lagging M, Negro F, Zeuzem S, Ferrari C, Pawlotsky JM, Neumann AU, Schalm SW, de Knegt RJ; DITTO-HCV Study Group. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study. BMC Gastroenterol 2012;12:11. [PMID: 22292521 DOI: 10.1186/1471-230X-12-11] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
106 Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon. 2011;11:968-974. [PMID: 22368680 DOI: 10.5812/kowsar.1735143x.789] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
107 Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005;39:S3-8. [PMID: 15597025 DOI: 10.1097/01.mcg.0000145494.76305.11] [Cited by in Crossref: 73] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]